Find Research Outputs

Search concepts
Selected filters
2019

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer

Takada, K., Toyokawa, G., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Wakasu, S., Haro, A., Osoegawa, A., Tagawa, T., Oda, Y., Nakanishi, Y. & Mori, M., Dec 1 2019, In : Scientific reports. 9, 1, 13362.

Research output: Contribution to journalArticle

Open Access
Fluorodeoxyglucose F18
Non-Small Cell Lung Carcinoma
Cell Death
Biomarkers
Antibodies
2016
25 Citations (Scopus)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., Satoh, T., Okamoto, I., Nishio, K., Tamura, T. & Nakagawa, K., Jan 1 2016, In : Oncotarget. 7, 3, p. 3453-3460 8 p.

Research output: Contribution to journalArticle

Colorectal Neoplasms
Epidermal Growth Factor Receptor
DNA
Neoplasms
Antibodies
2018
12 Citations (Scopus)

Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers

Akamine, T., Takada, K., Toyokawa, G., Kinoshita, F., Matsubara, T., Kozuma, Y., Haratake, N., Takamori, S., Hirai, F., Tagawa, T., Okamoto, T., Yoneshima, Y., Okamoto, I., Shimokawa, M., Oda, Y., Nakanishi, Y. & Maehara, Y., Mar 2018, In : Surgical Oncology. 27, 1, p. 88-94 7 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
C-Reactive Protein
Blood Proteins
Ligands
Lymphocytes
2017
25 Citations (Scopus)

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations

Iwama, E., Sakai, K., Azuma, K., Harada, T., Harada, D., Nosaki, K., Hotta, K., Ohyanagi, F., Kurata, T., Fukuhara, T., Akamatsu, H., Goto, K., Shimose, T., Kishimoto, J., Nakanishi, Y., Nishio, K. & Okamoto, I., Jan 1 2017, In : Annals of Oncology. 28, 1, p. 136-141 6 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Polymerase Chain Reaction
Mutation
DNA
Alleles
2018
686 Citations (Scopus)

Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. C., Gray, J. E., Lee, S. M. & 4 others, Hodge, R., Marotti, M., Rukazenkov, Y. & Ramalingam, S. S., Jan 11 2018, In : New England Journal of Medicine. 378, 2, p. 113-125 13 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Confidence Intervals
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
2019

Identification of genomic alterations acquired during treatment with EGFR-TKIs in non-small cell lung cancer

Kubo, N., Harada, T., Shiraishi, Y., Nosaki, K., Nakagaki, N., Takeshita, M., Ouchi, H., Iwama, E., Tanaka, K., Okamoto, I., Sasaki, H. & Nakanishi, Y., Feb 2019, In : Anticancer research. 39, 2, p. 671-677 7 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Exome
2016
15 Citations (Scopus)

Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301

Sakata, S., Saeki, S., Okamoto, I., Otsubo, K., Komiya, K., Morinaga, R., Yoneshima, Y., Koga, Y., Enokizu, A., Kishi, H., Hirosako, S., Yamaguchi, E., Aragane, N., Fujii, S., Harada, T., Iwama, E., Semba, H., Nakanishi, Y. & Kohrogi, H., Sep 1 2016, In : Lung Cancer. 99, p. 41-45 5 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Thorax
docetaxel
Confidence Intervals
Febrile Neutropenia
2019

Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti–PD-1 therapy

Ikematsu, Y., Tanaka, K., Yanagihara, T., Liu, R., Inoue, H., Yoneshima, Y., Ota, K., Iwama, E., Takata, S., Hata, K., Takahata, Y., Wataya, H., Nakanishi, Y. & Okamoto, I., Dec 2019, In : Lung Cancer. 138, p. 58-64 7 p.

Research output: Contribution to journalArticle

Pleural Effusion
Cytokines
T-Lymphocytes
Cell- and Tissue-Based Therapy
Neoplasms
2018
4 Citations (Scopus)

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis

Ide, M., Tanaka, K., Sunami, S., Asoh, T., Maeyama, T., Tsuruta, N., Nakanishi, Y. & Okamoto, I., Nov 2018, In : Thoracic Cancer. 9, 11, p. 1519-1521 3 p.

Research output: Contribution to journalArticle

Idiopathic Pulmonary Fibrosis
Non-Small Cell Lung Carcinoma
Pleurisy
Respiratory Function Tests
Neoplasms
1 Citation (Scopus)

Radiological features of programmed cell death-ligand 2-positive lung adenocarcinoma: A single-institution retrospective study

Takada, K., Toyokawa, G., Azuma, K., Takamori, S., Jogo, T., Hirai, F., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., Nov 1 2018, In : In Vivo. 32, 6, p. 1541-1550 10 p.

Research output: Contribution to journalArticle

Fluorodeoxyglucose F18
Cell death
Tomography
Cell Death
Retrospective Studies
2016
5 Citations (Scopus)

Characteristics of smoking patients with lung cancer with emphysematous bullae

Iwama, E., Okamoto, I., Yabuuchi, H., Takayama, K., Harada, T., Matsuo, Y., Tokunaga, S., Baba, E. & Nakanishi, Y., Jan 1 2016, In : Journal of Thoracic Oncology. 11, 9, p. 1586-1590 5 p.

Research output: Contribution to journalArticle

Blister
Lung Neoplasms
Smoking
Emphysema
Epidermal Growth Factor
2019
2 Citations (Scopus)

Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor

Hino, T., Kamitani, T., Sagiyama, K., Yamasaki, Y., Okamoto, I., Tagawa, T., Ijichi, K., Yamamoto, H., Yabuuchi, H. & Honda, H., Jan 1 2019, In : European Journal of Radiology Open. 6, p. 72-77 6 p.

Research output: Contribution to journalArticle

Neoplasms
Pleura
Mediastinum
Differential Diagnosis
Malignant Mesothelioma
2018
3 Citations (Scopus)

Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer

Kawano, Y., Sasaki, T., Yamaguchi, H., Hirano, K., Horiike, A., Satouchi, M., Hosokawa, S., Morinaga, R., Komiya, K., Inoue, K., Fujita, Y., Toyozawa, R., Kimura, T., Takahashi, K., Nishikawa, K., Kishimoto, J., Nakanishi, Y. & Okamoto, I., Nov 2018, In : Lung Cancer. 125, p. 136-141 6 p.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Radiotherapy
Leukopenia
Confidence Intervals
2019

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA

Otsubo, K., Sakai, K., Takeshita, M., Harada, D., Azuma, K., Ota, K., Akamatsu, H., Goto, K., Horiike, A., Kurata, T., Nakagaki, N., Nosaki, K., Iwama, E., Nakanishi, Y., Nishio, K. & Okamoto, I., Jan 1 2019, In : Oncologist. 24, 8, p. 1022-1026 5 p.

Research output: Contribution to journalArticle

High-Throughput Nucleotide Sequencing
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
DNA
2016
46 Citations (Scopus)

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

Yonesaka, K., Hirotani, K., Kawakami, H., Takeda, M., Kaneda, H., Sakai, K., Okamoto, I., Nishio, K., Jänne, P. A. & Nakagawa, K., Feb 18 2016, In : Oncogene. 35, 7, p. 878-886 9 p.

Research output: Contribution to journalArticle

Neuregulin-1
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Monoclonal Antibodies
Protein-Tyrosine Kinases
2017
16 Citations (Scopus)

Discrepancy in programmed cell death-ligand 1 between primary and metastatic non-small cell lung cancer

Takamori, S., Toyokawa, G., Okamoto, I., Takada, K., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Katsura, M., Mukae, N., Shoji, F., Okamoto, T., Oda, Y., Iwaki, T., Iihara, K., Nakanishi, Y. & Maehara, Y., Aug 2017, In : Anticancer research. 37, 8, p. 4223-4228 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Cell Death
Ligands
Radiotherapy
Brain
2019

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Yonesaka, K., Iwama, E., Hayashi, H., Suzuki, S., Kato, R., Watanabe, S., Takahama, T., Tanizaki, J., Tanaka, K., Takeda, M., Sakai, K., Azuma, K., Chiba, Y., Atagi, S., Nishio, K., Okamoto, I. & Nakagawa, K., Dec 1 2019, In : Scientific reports. 9, 1, 19501.

Research output: Contribution to journalArticle

Open Access
Neuregulin-1
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Proportional Hazards Models
5 Citations (Scopus)

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma

Matsubara, T., Takada, K., Azuma, K., Takamori, S., Toyokawa, G., Haro, A., Osoegawa, A., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., Jun 15 2019, In : Annals of Surgical Oncology. 26, 6, p. 1925-1933 9 p.

Research output: Contribution to journalArticle

Squamous Cell Carcinoma
Ligands
Lung
CD274 Antigen
Immunotherapy

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

Sugawara, S., Nakagawa, K., Yamamoto, N., Nokihara, H., Ohe, Y., Nishio, M., Takahashi, T., Goto, K., Maemondo, M., Ichinose, Y., Seto, T., Sakai, H., Gemma, A., Imamura, F., Shingyoji, M., Saka, H., Inoue, A., Takeda, K., Okamoto, I., Kiura, K. & 2 others, Morita, S. & Tamura, T., May 15 2019, In : International Journal of Clinical Oncology. 24, 5, p. 485-493 9 p.

Research output: Contribution to journalArticle

Open Access
docetaxel
Far East
Platinum
Non-Small Cell Lung Carcinoma
Lung Neoplasms
2018
58 Citations (Scopus)

CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer

Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., Okamoto, I., Leighl, N., Hodge, R., McKeown, A., Brown, A. P., Rukazenkov, Y., Ramalingam, S. S. & Vansteenkiste, J., Nov 20 2018, In : Journal of Clinical Oncology. 36, 33, p. 3290-3297 8 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
osimertinib
Disease-Free Survival
2019
1 Citation (Scopus)

Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients

Nogami, N., Nishio, M., Okamoto, I., Enatsu, S., Suzukawa, K., Takai, H., Nakagawa, K. & Tamura, T., Jan 2019, In : Respiratory Investigation. 57, 1, p. 27-33 7 p.

Research output: Contribution to journalArticle

Pemetrexed
Carboplatin
Non-Small Cell Lung Carcinoma
Maintenance
Therapeutics
2018
14 Citations (Scopus)

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Okamoto, I., Morita, S., Tashiro, N., Imamura, F., Inoue, A., Seto, T., Yamamoto, N., Ohe, Y., Nakagawa, K. & Fukuoka, M., Mar 2018, In : Lung Cancer. 117, p. 14-19 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Mutation
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Survival
2019
Open Access
Non-Small Cell Lung Carcinoma
Immunotherapy
Radiation
Drug Therapy
Therapeutics
3 Citations (Scopus)

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C. H., Park, K., Novello, S., Nadal, E., Imamura, F., Yoh, K., Shih, J. Y., Au, K. H., Moro-Sibilot, D., Enatsu, S., Zimmermann, A., Frimodt-Moller, B., Visseren-Grul, C., Reck, M. & 96 others, Chu, Q., Cortot, A., Pujol, J. L., Fabre, E., Lamour, C., Bischoff, H., Kollmeier, J., Kimmich, M., Engel-Riedel, W., Hammerschmidt, S., Schütte, W., Syrigos, K., Ho, J. C. M., Au, K. H., Ardizzoni, A., Pasello, G., Gregorc, V., Del Conte, A., Galetta, D., Takahashi, T., Kumagai, T., Hotta, K., Goto, Y., Hosomi, Y., Sakai, H., Takiguchi, Y., Kim, Y. H., Kurata, T., Yamaguchi, H., Daga, H., Okamoto, I., Satouchi, M., Ikeda, S., Kasahara, K., Atagi, S., Azuma, K., Aoe, K., Horio, Y., Yamamoto, N., Tanaka, H., Watanabe, S., Nogami, N., Ozaki, T., Koyama, R., Hirashima, T., Kaneda, H., Tomii, K., Fujita, Y., Seike, M., Nishimura, N., Kato, T., Ichiki, M., Saka, H., Hirano, K., Nakahara, Y., Sugawara, S., Kim, S. W., Min, Y. J., Lee, H. W., Kang, J. H., An, H. J., Lee, K. H., Kim, J. S., Lee, G. W., Lee, S. Y., Alexandru, A., Udrea, A. A., Juan-Vidal, Ó., Nadal-Alforja, E., Gil-Bazo, I., Ponce-Aix, S., Rubio-Viqueira, B., Alonso Garcia, M., Felip Font, E., Fuentes Pradera, J., Coves Sarto, J., Lin, M. C., Su, W. C., Hsia, T. C., Chang, G. C., Wei, Y. F., Su, J., Cicin, I., Goksel, T., Harputluoglu, H., Ozyilkan, O., Henning, I., Popat, S., Hatcher, O., Mileham, K., Acoba, J., Garon, E., Jung, G., Raj, M., Martin, W. & Dakhil, S., Dec 2019, In : The Lancet Oncology. 20, 12, p. 1655-1669 15 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Placebos
Disease-Free Survival
ramucirumab
Erlotinib Hydrochloride
2016
13 Citations (Scopus)

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

Hibi, M., Kaneda, H., Tanizaki, J., Sakai, K., Togashi, Y., Terashima, M., De Velasco, M. A., Fujita, Y., Banno, E., Nakamura, Y., Takeda, M., Ito, A., Mitsudomi, T., Nakagawa, K., Okamoto, I. & Nishio, K., Nov 1 2016, In : Cancer Science. 107, 11, p. 1667-1676 10 p.

Research output: Contribution to journalArticle

Fibroblast Growth Factor Receptors
Squamous Cell Carcinoma
Lung
Genes
Cell Line
2018

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay

Kimura, S., Tanaka, K., Harada, T., Liu, R., Shibahara, D., Kawano, Y., Nakanishi, Y. & Okamoto, I., Nov 2018, In : Cancer Science. 109, 11, p. 3657-3661 5 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Mutation
Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
BIBW 2992
1 Citation (Scopus)
Therapeutic Uses
Platinum
Non-Small Cell Lung Carcinoma
Perfusion
Tomography
2017
8 Citations (Scopus)

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer

Otsubo, K., Nosaki, K., Imamura, C. K., Ogata, H., Fujita, A., Sakata, S., Hirai, F., Toyokawa, G., Iwama, E., Harada, T., Seto, T., Takenoyama, M., Ozeki, T., Mushiroda, T., Inada, M., Kishimoto, J., Tsuchihashi, K., Suina, K., Nagano, O., Saya, H. & 2 others, Nakanishi, Y. & Okamoto, I., Sep 2017, In : Cancer Science. 108, 9, p. 1843-1849 7 p.

Research output: Contribution to journalArticle

Pemetrexed
Sulfasalazine
Non-Small Cell Lung Carcinoma
Cisplatin
Neoplastic Stem Cells
6 Citations (Scopus)

A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study

Hayashi, H., Chiba, Y., Sakai, K., Fujita, T., Yoshioka, H., Sakai, D., Kitagawa, C., Naito, T., Takeda, K., Okamoto, I., Mitsudomi, T., Kawakami, Y., Nishio, K., Nakamura, S., Yamamoto, N. & Nakagawa, K., Nov 2017, In : Clinical Lung Cancer. 18, 6, p. 719-723 5 p.

Research output: Contribution to journalArticle

Pemetrexed
erbB-1 Genes
Carboplatin
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
2016
15 Citations (Scopus)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

Azuma, K., Hirashima, T., Yamamoto, N., Okamoto, I., Takahashi, T., Nishio, M., Hirata, T., Kubota, K., Kasahara, K., Hida, T., Yoshioka, H., Nakanishi, K., Akinaga, S., Nishio, K., Mitsudomi, T. & Nakagawa, K., Jul 2016, In : ESMO Open. 1, 4, e000063.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Hepatocyte Growth Factor
Disease-Free Survival
2019

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)

Fukuda, M., Kitazaki, T., Ogawara, D., Ichiki, M., Mukae, H., Maruyama, R., Nakagaki, N., Shimada, M., Ikeda, T., Kishimoto, J., Harada, T., Seto, T., Ebi, N., Takayama, K., Okamoto, I., Ichinose, Y. & Sugio, K., Jun 2019, In : Lung Cancer. 132, p. 1-8 8 p.

Research output: Contribution to journalArticle

Pemetrexed
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Disease-Free Survival
Bevacizumab
2017
13 Citations (Scopus)

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

Iwama, E., Goto, Y., Murakami, H., Harada, T., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., Ono, M., Okazaki, A., Akamatsu, H., Morinaga, R., Ushijima, S., Shimose, T., Tokunaga, S., Hamada, A., Yamamoto, N. & 3 others, Nakanishi, Y., Sugio, K. & Okamoto, I., Jul 2017, In : Journal of Thoracic Oncology. 12, 7, p. 1161-1166 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Lung
Confidence Intervals
Patient Safety
CH5424802
2018
4 Citations (Scopus)

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Iwama, E., Nakanishi, Y. & Okamoto, I., Mar 4 2018, In : Expert Review of Anticancer Therapy. 18, 3, p. 267-276 10 p.

Research output: Contribution to journalReview article

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Therapeutics
2019
4 Citations (Scopus)

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients

Takamori, S., Takada, K., Azuma, K., Jogo, T., Shimokawa, M., Toyokawa, G., Hirai, F., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., Jun 15 2019, In : Annals of Surgical Oncology. 26, 6, p. 1916-1924 9 p.

Research output: Contribution to journalArticle

Ligands
Adenocarcinoma of lung
Immunotherapy
Disease-Free Survival
Survival
2018
9 Citations (Scopus)

PD-L2 expression as a potential predictive biomarker for the response to anti-PD-1 drugs in patients with non-small cell lung cancer

Takamori, S., Takada, K., Toyokawa, G., Azuma, K., Shimokawa, M., Jogo, T., Yamada, Y., Hirai, F., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., Oct 2018, In : Anticancer research. 38, 10, p. 5897-5901 5 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Cell Death
Biomarkers
Ligands
Pharmaceutical Preparations
9 Citations (Scopus)

Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing

Iwama, E., Sakai, K., Azuma, K., Harada, D., Nosaki, K., Hotta, K., Nishio, M., Kurata, T., Fukuhara, T., Akamatsu, H., Goto, K., Shimose, T., Kishimoto, J., Nakanishi, Y., Nishio, K. & Okamoto, I., Dec 2018, In : Cancer Science. 109, 12, p. 3921-3933 13 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Polymerase Chain Reaction
Mutation
Neoplasms
2019
5 Citations (Scopus)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset

Ohe, Y., Imamura, F., Nogami, N., Okamoto, I., Kurata, T., Kato, T., Sugawara, S., Ramalingam, S. S., Uchida, H., Hodge, R., Vowler, S. L., Walding, A. & Nakagawa, K., Jan 1 2019, In : Japanese journal of clinical oncology. 49, 1, p. 29-36 8 p.

Research output: Contribution to journalArticle

Standard of Care
Confidence Intervals
Disease-Free Survival
Safety
Therapeutics
2020

Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation

Tsutsumi, H., Yoneshima, Y., Ota, K., Otsubo, K., Iwama, E., Inoue, H., Tanaka, K., Nakanishi, Y. & Okamoto, I., Jan 2020, In : Clinical Lung Cancer. 21, 1, p. e21-e24

Research output: Contribution to journalArticle

2018
2 Citations (Scopus)

Anticancer drug treatment for advanced lung cancer with interstitial lung disease

Otsubo, K., Okamoto, I., Hamada, N. & Nakanishi, Y., Jul 2018, In : Respiratory Investigation. 56, 4, p. 307-311 5 p.

Research output: Contribution to journalReview article

Interstitial Lung Diseases
Lung Neoplasms
Pharmaceutical Preparations
Drug Therapy
Therapeutics
2016
31 Citations (Scopus)

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial

Takeda, M., Yamanaka, T., Seto, T., Hayashi, H., Azuma, K., Okada, M., Sugawara, S., Daga, H., Hirashima, T., Yonesaka, K., Urata, Y., Murakami, H., Saito, H., Kubo, A., Sawa, T., Miyahara, E., Nogami, N., Nakagawa, K., Nakanishi, Y. & Okamoto, I., Apr 1 2016, In : Cancer. 122, 7, p. 1050-1059 10 p.

Research output: Contribution to journalArticle

docetaxel
Non-Small Cell Lung Carcinoma
Disease Progression
Japan
Drug Therapy
2019
1 Citation (Scopus)

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

Udagawa, H., Akamatsu, H., Tanaka, K., Takeda, M., Kanda, S., Kirita, K., Teraoka, S., Nakagawa, K., Fujiwara, Y., Yasuda, I., Okubo, S., Shintani, M., Kosloski, M. P., Scripture, C., Tamura, T. & Okamoto, I., Sep 2019, In : Lung Cancer. 135, p. 145-150 6 p.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Pharmacokinetics
Safety
Hypoalbuminemia
Retreatment
2018
6 Citations (Scopus)

Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non–Small Cell Lung Cancer

Shibahara, D., Tanaka, K., Iwama, E., Kubo, N., Ota, K., Azuma, K., Harada, T., Fujita, J., Nakanishi, Y. & Okamoto, I., Jul 2018, In : Journal of Thoracic Oncology. 13, 7, p. 926-937 12 p.

Research output: Contribution to journalArticle

Oncogenes
Non-Small Cell Lung Carcinoma
Cell Death
Ligands
STAT3 Transcription Factor
2019
2 Citations (Scopus)

Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies

Yoneshima, Y., Tanaka, K., Shiraishi, Y., Hata, K., Watanabe, H., Harada, T., Otsubo, K., Iwama, E., Inoue, H., Masuda, S., Nakanishi, Y. & Okamoto, I., Apr 2019, In : Lung Cancer. 130, p. 5-9 5 p.

Research output: Contribution to journalArticle

Antinuclear Antibodies
Non-Small Cell Lung Carcinoma
Safety
Autoimmune Diseases
Disease-Free Survival
2017
18 Citations (Scopus)

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer

Hidaka, N., Iwama, E., Kubo, N., Harada, T., Miyawaki, K., Tanaka, K., Okamoto, I., Baba, E., Akashi, K., Sasaki, H. & Nakanishi, Y., Jun 1 2017, In : Lung Cancer. 108, p. 75-82 8 p.

Research output: Contribution to journalArticle

erbB-1 Genes
Non-Small Cell Lung Carcinoma
Alleles
Mutation
Protein-Tyrosine Kinases
2019

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer

Tsuchiya-Kawano, Y., Sasaki, T., Yamaguchi, H., Hirano, K., Horiike, A., Satouchi, M., Hosokawa, S., Morinaga, R., Komiya, K., Inoue, K., Fujita, Y., Toyozawa, R., Kimura, T., Takahashi, K., Nishikawa, K., Kishimoto, J., Nakanishi, Y. & Okamoto, I., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Open Access
Carboplatin
Non-Small Cell Lung Carcinoma
Radiotherapy
Survival
Disease-Free Survival
1 Citation (Scopus)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Park, K., Wan-Teck Lim, D., Okamoto, I. & Yang, J. C. H., Apr 1 2019, In : Therapeutic Advances in Medical Oncology. 11

Research output: Contribution to journalReview article

Open Access
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Lung
Therapeutics

Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)

Nishio, M., Sugawara, S., Atagi, S., Akamatsu, H., Sakai, H., Okamoto, I., Takayama, K., Hayashi, H., Nakagawa, Y. & Kawakami, T., Nov 2019, In : Clinical Lung Cancer. 20, 6, p. 469-476.e1

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Safety
Drug Therapy
Survival
MPDL3280A

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K. & Mitsudomi, T., Dec 1 2019, In : Annals of Oncology. 30, 12, p. 1978-1984 7 p.

Research output: Contribution to journalArticle

docetaxel
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Cisplatin
Mutation
2016
29 Citations (Scopus)

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: A retrospective analysis for 1660 Japanese patients

Inoue, A., Yoshida, K., Morita, S., Imamura, F., Seto, T., Okamoto, I., Nakagawa, K., Yamamoto, N., Muto, S. & Fukuoka, M., Jan 1 2016, In : Japanese journal of clinical oncology. 46, 5, p. 462-467 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Mutation
Survival
73 Citations (Scopus)

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang, J. C. H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C. P., Yamamoto, N., Feng, J., O'Byrne, K., Lu, S., Hirsh, V., Huang, Y., Sebastian, M., Okamoto, I., Dickgreber, N., Shah, R., Märten, A., Massey, D., Wind, S. & 1 others, Wu, Y. L., Jan 1 2016, In : Annals of Oncology. 27, 11, p. 2103-2110 8 p.

Research output: Contribution to journalArticle

Safety
Lung
Mutation
Disease-Free Survival
Non-Small Cell Lung Carcinoma